The current clinical pipeline for new antibiotics fails to address the biggest threats increasingly posed by drug-resistant Gram-negative bacteria identified by the World Health Organization as a global health priority. As companies continue to leave the field of antibiotic development, many researchers have retired or focused their activities on other areas. This ‘discovery void’ risks the loss of invaluable experience and knowledge crucial for the discovery, research and development of new antimicrobial treatments. The Global Antibiotic R&D Partnership (GARDP) has created REVIVE to ensure that knowledge is retained, and the antimicrobial R&D community is supported online to connect, share, and acquire information. Through REVIVE, GARDP is helping advance the development of new treatments by freely sharing the knowledge and skills of experts to those with an interest in antimicrobial R&D.

REVIVE aims to improve, accelerate, and streamline antimicrobial drug discovery and R&D by directly connecting researchers with both established and retired antimicrobial researchers and developers, and to facilitate learning and knowledge exchange.

Facilitate learning:
REVIVE has a strong educational focus. Through a continuing series of webinars led by experts in their field, REVIVE has reached more than 1100 individuals. Topics discussed in the first five webinars have included clinical development pathways of antibacterial drugs, PK-PD for antimicrobial development, safety as a part of antibacterial drug design, and an overview of NIAD resources to facilitate discovery & development of anti-infectives.

Future REVIVE webinars will include:
- Antibacterial drugs: Clinical development for non-developers Part 3: Antibacterial drug enhancer combinations and non-traditional products (Ian Friedland, Sumathi Nambari, Mair Powell, David Siahaes)
- Mining chemical libraries for new antibacterials (Carl Balibar)

Recordings of past webinars as well as dates and registration links of future webinars can be found on revive.gardp.org/webinars.

Connect people:
REVIVE provides all those in the antimicrobial field, from academia, start-ups, biotech and large companies, with access to scientific advice from experienced drug developers. Those working on antimicrobials can engage with REVIVE’s expert group via the website’s ‘Talk to an expert’ interface (revive.gardp.org/talk-to-an-expert). REVIVE also provides a forum for exchange between early-career researchers, drug developers experienced in other disease areas now refocusing their research to address the antimicrobial resistance crisis, and clinical and non-clinical researchers. The REVIVE expert network is continuously growing with the aim of representing those from across the world and different scientific and medical specialties.

The ‘Talk to an expert’ interface:
- Users submit questions via the ‘Talk to an expert’ interface
- We review the requests and invite one or more suitable experts to respond
- The invited expert(s) accept the requests if they are able to offer advice
- Once an expert accepts a request, the user will be able to connect with them directly

GARDP also co-organizes sessions (e.g. panel discussions or meet-the-expert sessions) at conferences such as the BSAC 2019 Conference, ASM Microbe and ASM/ESCMID. As a not-for-profit organization with a global scope, GARDP makes recordings of its conference sessions available on revive.gardp.org/conferences.

Share knowledge:
Through REVIVE’s blogs, launched in November 2018, GARDP aims to share knowledge and stimulate discussions on highly relevant topics in the antimicrobial resistance (AMR) space. As of February 2019, six blog posts by high-profile guest authors have been published on revive.gardp.org/blog. GARDP welcomes proposals for new blog posts.

More than one model to stimulate antimicrobial drug development by Jim O’Neill
Recent approvals – do they make a difference? by Ursula Theuretzbacher
Why we need to prioritize developing antibiotics for children by Manica Balasegaram
Time to pull out all the stops in the fight against superbugs by Kevin Outterson
Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance by Sarah Paulin and Peter Beyer
The REPAIR Impact Fund: Reflections from the first year by Aleks Engel

During 2019, REVIVE will launch an open-access comprehensive repository of resources for antimicrobial researchers. It will comprise new bespoke materials as well as links to existing resources in an easily accessible format.

About GARDP:
GARDP is a not-for-profit research and development partnership that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative (DNDi) in May 2016, GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage R&D of new antimicrobial agents and diagnostics.

Global Antibiotic R&D Partnership (GARDP)
15 Chemin Louis-Dunant | 1202 Geneva | Switzerland | contact@gardp.org

revive@gardp.org | revive.gardp.org & www.gardp.org | twitter.com/gardp_amr | www.linkedin.com/company/gardp/